Moleculin Biotech, Inc.
MBRXNasdaq
$2.10
↓ -3.2%Jul 17 close · end-of-day
Price
1Y↓ -86.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$40.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-266.8%
ROIC
-438.9%
Debt / Equity
—
Net Cash
$10.3M
Return 1Y
-90.0%
Company profile
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the. treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in clinical trials for brain tumors and pediatric brain tumors.
- CEO
- Walter V. Klemp
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Texas
- Website
- moleculin.com
Management & directors
- Foster Jonathan P.Chief Financial Officer
- Klemp Walter VCEO and President
- Picker Donald HChief Science Officer
Roles derived from SEC Form 4 filings.
Earnings
MBRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.7M | -$23.0M | -$30.6M | -$29.6M | -$26.6M | -$25.1M |
| Net income | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$26.0M | -$33.6M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$17.8M | -$19.0M | -$27.6M | -$23.6M | -$23.9M | -$22.7M |
| Free cash flow | -$18.1M | -$19.0M | -$27.7M | -$23.7M | -$23.9M | -$22.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.2M | -$7.1M | -$6.6M | -$5.9M | -$5.7M | -$5.9M | -$7.5M | -$7.9M |
| Net income | -$6.0M | -$7.0M | -$6.6M | -$5.9M | -$17.8M | -$25.4M | $15.6M | -$12.8M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$5.9M | -$6.1M | -$5.1M | -$4.6M | -$5.6M | -$7.2M | -$5.4M | -$6.1M |
| Free cash flow | -$6.0M | -$6.1M | -$5.1M | -$4.6M | -$5.6M | -$7.2M | -$5.4M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | KLEMP WALTER V· CEO and President | Tax withholding | 88 | $3.12 | $274.56 | filing |
| 2026-06-22 | Foster Jonathan P.· Chief Financial Officer | Tax withholding | 41 | $3.12 | $127.92 | filing |
| 2026-06-22 | PICKER DONALD H· Chief Science Officer | Tax withholding | 21 | $3.12 | $65.52 | filing |
| 2026-06-22 | PICKER DONALD H· Chief Science Officer | Option exercise | 71 | — | — | filing |
| 2026-06-22 | KLEMP WALTER V· CEO and President | Option exercise | 360 | — | — | filing |
| 2026-06-22 | Foster Jonathan P.· Chief Financial Officer | Option exercise | 174 | — | — | filing |
| 2026-06-20 | KLEMP WALTER V· CEO and President | Tax withholding | 37 | $2.88 | $106.56 | filing |
| 2026-06-20 | Foster Jonathan P.· Chief Financial Officer | Tax withholding | 31 | $2.88 | $89.28 | filing |
| 2026-06-20 | PICKER DONALD H· Chief Science Officer | Tax withholding | 13 | $2.88 | $37.44 | filing |
| 2026-06-20 | KLEMP WALTER V· CEO and President | Option exercise | 150 | — | — | filing |
| 2026-06-20 | Foster Jonathan P.· Chief Financial Officer | Option exercise | 109 | — | — | filing |
| 2026-06-20 | PICKER DONALD H· Chief Science Officer | Option exercise | 44 | — | — | filing |
| 2025-11-04 | KLEMP WALTER V· CEO and President | Tax withholding | 7,001 | $0.50 | $3,479.50 | filing |
| 2025-11-04 | Foster Jonathan P.· Chief Financial Officer | Option exercise | 5,023 | $0.50 | $2,496.43 | filing |
| 2025-11-04 | PICKER DONALD H· Chief Science Officer | Tax withholding | 2,131 | $0.50 | $1,059.11 | filing |
| 2025-11-04 | Foster Jonathan P.· Chief Financial Officer | Option exercise | 20,625 | — | — | filing |
| 2025-11-04 | PICKER DONALD H· Chief Science Officer | Option exercise | 8,750 | — | — | filing |
| 2025-11-04 | KLEMP WALTER V· CEO and President | Option exercise | 28,750 | — | — | filing |
| 2025-06-23 | KLEMP WALTER V· CEO and President | Buy | 675,675 | $0.37 | $249,999.75 | filing |
| 2025-06-23 | Foster Jonathan P.· Chief Financial Officer | Buy | 270,270 | $0.37 | $99,999.90 | filing |
| 2025-06-22 | KLEMP WALTER V· CEO and President | Tax withholding | 2,190 | $0.27 | $584.73 | filing |
| 2025-06-22 | Foster Jonathan P.· Chief Financial Officer | Tax withholding | 1,054 | $0.27 | $281.42 | filing |
| 2025-06-22 | PICKER DONALD H· Chief Science Officer | Tax withholding | 430 | $0.27 | $114.81 | filing |
| 2025-06-22 | KLEMP WALTER V· CEO and President | Option exercise | 8,990 | — | — | filing |
| 2025-06-22 | PICKER DONALD H· Chief Science Officer | Option exercise | 1,766 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.